Clinical Trial Update: Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with solid tumors, including Ewing sarcoma and other sarcomas, has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Sarcoma

Drugs mentioned

• Figitumumab (figitumumab)

Snippet

Sponsor: Pfizer | Conditions: Sarcoma, Ewing's | Phase 1 | Status: COMPLETED | Results posted: 2013-12-17